Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

At Investor Meeting, Spotlight is on Bristol-Myers CEO-Designate Lamberto Andreotti --and Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Five new medicines, including a melanoma treatment, are projected to be launched by 2012 to replace sales that will be lost to generics

You may also be interested in...



For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll

The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result

For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll

The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result

For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll

The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel